Related Experiment Video
Updated: Aug 21, 2026
The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
Published on: May 17, 2024
A randomized, double-blind, placebo-controlled trial of casein protein hydrolysate (C12 peptide) in human essential
Raymond R Townsend1, Christopher B McFadden, Virginia Ford
1Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania, USA. townsend@mail.med.upenn.edu
Background:
Many patients seek complementary medicine treatments like neutraceuticals for common conditions such as hypertension.
Methods:
We conducted a placebo-controlled prospective randomized crossover study in 10 hypertensive subjects to determine whether a single dose of a hydrolysate of bovine milk protein (designated C12 peptide; low and high dose), either alone or combined with alginic acid (low and high dose), reduced daytime blood pressure (BP), as determined by ambulatory BP monitoring.
Results:
Within the five treatment regimens a significant reduction of 9.2 +/- 3.2 mm Hg in systolic BP at h 6 compared with h 2 occurred on the higher dose of alginic acid (1754 mg) combined with C12 (P = .02). The C12 peptide with the higher dose of alginic acid also showed a significant reduction of 6.0 +/- 2.0 mm Hg in diastolic BP at h 6 compared with h 2 (P = .015).
Conclusions:
These preliminary data are encouraging and deserve testing in a larger and longer treatment trial.
